Boehringer Ingelheim GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
Singapore has granted approval for a Phase I/II trial of Arcturus’s next generation mRNA COVID-19 vaccine candidates, hot on the heels of a similar approval from Vietnam earlier this week. The biotech’s share price duly rocketed, but there may be more at play.
Germany’s Boehringer Ingelheim highlighted its clinical-stage research efforts in neuropsychiatry and COVID-19 when describing its first half financial results as solid, despite the continuing impact of the pandemic.
Bausch Health says it’s continuing a recovery from the disaster previous management left, when the firm operated as Valeant Pharmaceuticals, even though it reported a $595m net loss for Q2. “We've been trying to solve this debt issue for the company,” says CEO Joseph Papa.
Market Intel: Expanding Applications And Improved Offerings To Drive Robotically Assisted Surgery Market
The global market for robotically assisted surgical devices will reach $11.5bn by 2025 as system improvements drive sales.
- Other Names / Subsidiaries
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)